Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment

Status Not yet recruiting

Clinical Trial Summary

The study team will assess the efficacy of platelet-rich plasma therapy, a special blood product which is from the participant's own body, in the treatment of androgenic alopecia (also known as male pattern hair loss) in females.

Clinical Trial Description

Androgenic alopecia, or male-pattern hair loss affects both men and women. This hair loss pattern is typically characterized by thinning at the crown of scalp and/or M-shaped hair line in males or diffuse thinning throughout in females. Platelet-rich plasma (PRP) therapy has recently been studied as a hair rejuvenation therapy in patients with non-inflammatory alopecia. Though the mechanism of action is not well understood, PRP is thought to promote angiogenesis and enhance blood flow around hair follicles via platelet-derived growth factor (PDGF), transforming growth factor (TGF), and vascular endothelial growth factor (VEGF). The primary objective of the study is to determine whether PRP, administered once monthly for 3 months improves clinical outcomes and quality of life in females with androgenic alopecia. This is a randomized, placebo-controlled, double-blind, half-head, single center clinical study where sixteen subjects with androgenic alopecia will be recruited. Dermatology Life Quality Index will be assessed at several time points. Disease severity will be measured using the Severity of Alopecia Tool (SALT), Alopecia Density and Extent Score (ALODEX); Trichoscan images will be captured to document participants' clinical progress. Adverse events will be recorded at each visit, treatment will be discontinued if any subject experience a serious adverse event. Treatment visits will take place at baseline, 4 weeks (1 month), 8 weeks (2 months), and 12 weeks (3 month). A follow-up, non-treatment visit will take place at 24 weeks (6 months). The study team hypothesizes that PRP will improve DLQI, SALT, ALODEX, hair count (number of hairs/0.65 cm2), hair density (number of hairs/cm2), hair diameter, anagen to telogen ratio, and vellus hair to terminal hair ratio in female subjects with androgenic alopecia. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03474718
Study type	Interventional
Source	Wake Forest University Health Sciences
Contact	Research Coordinator
Phone	336-716-2903
Email	irichard@wakehealth.edu
Status	Not yet recruiting
Phase	Early Phase 1
Start date	May 2024
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06110377` - MALE HAIR LOSS - Treatment With Dutasteride Mesotherapy x Dutasteride MMP Technique (Injections With Tattoo Machine)	Phase 4
Recruiting	`NCT05611593` - Study to Evaluate Safety & Usability of a New Formulation for Male Androgenetic Alopecia	Phase 1
Completed	`NCT03676400` - Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia	N/A
Recruiting	`NCT05938569` - Computer-Assisted Hair Restoration Study Using ARTAS System	N/A
Not yet recruiting	`NCT06326359` - Autologous Stromal Vascular Fraction in Treatment of Male Androgenic Alopecia	N/A
Not yet recruiting	`NCT06292533` - Effectiveness of Ultrapulse for the Treatment of Androgenic Alopecia Among Malaysian: A Quasi-experimental Study	N/A
Recruiting	`NCT05426629` - Hydraderm for Androgenic Alopecia	Phase 4
Recruiting	`NCT05827991` - A Clinical Observation of 1565nm Non-ablative Fractional Laser in the Treatment of Androgenic Alopecia	N/A
Recruiting	`NCT05369481` - Comparison Between Efficacy of Topical Sildenafil 2% and Topical Minoxidil 5% in Treatment of Androgenic Alopecia	N/A
Completed	`NCT02824380` - Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia	Phase 1
Completed	`NCT06112782` - Keravive by Hydrafacial for Scalp Health and Enhanced Hair Quality	N/A
Completed	`NCT02594046` - The Effect of Allogeneic Human Adipose Derived Stem Cell Component Extract on Androgenic Alopecia	N/A
Recruiting	`NCT05435625` - Fractional Laser Versus Radiofrequency in Androgenetic Alopecia	N/A
Completed	`NCT05450861` - Effect of the Composition From Fish on Promoting Hair Growth	N/A
Completed	`NCT03506503` - Condensed Nanofat Grafting for Treatment of Androgenetic Alopecia	N/A
Completed	`NCT03467412` - To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin	Phase 2
Completed	`NCT01852487` - Effect of Pumpkin Seed Oil on Hair Growth in Men With Androgenetic Alopecia	N/A
Active, not recruiting	`NCT02914587` - Computer-Assisted Hair Implantation Using ARTAS System VS Manual Implantation Technique Hair Restoration Study	N/A
Completed	`NCT04341363` - Follicular Revival in Androgenic Alopecia: Evaluating Use of Micro-needling	N/A
Completed	`NCT04450602` - A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms